Pricing Log in Create free account
Friday 6 November 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue
−1.90%
EPS
−47.2%
Free cash flow
−30.3%
Total debt
−0.43%

Quarter to September 2026, against a year earlier

41.73 0.12 −0.29%
Market cap
$48.7B
P/E
92.6×
Fwd P/E
30.7×
Dividend yield
—
F-score
8/9
Altman Z
0.79
Beneish M
−2.35
Dividend safety
52/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Teva Pharmaceutical Industries Ltd. (TEVA) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Teva Pharmaceutical Industries Ltd. (TEVA) trades at a P/S ratio of 2.8×. Over the past ten years it has ranged from 0.3× (October 2019) to 3.0× (July 2015); the current reading is higher than 99% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.1× and below the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 2.1× 37.43%
FY2024 1.5× 99.96%
FY2023 0.8× 6.31%
FY2022 0.7× 18.07%
FY2021 0.6× (5.36%)
FY2020 0.6× 0.19%
FY2019 0.6× (26.53%)
FY2018 0.9× 26.57%
FY2017 0.7× (58.34%)
FY2016 1.6× (42.78%)

Quarterly newest first

Period P/S ratio Change
Sep 2026 2.7× 17.56%
Jun 2026 2.3× 13.58%
Mar 2026 2.0× (3.08%)
Dec 2025 2.1× 49.93%
43 more quarters

Against its own ten years

Low 0.3× High 3.0×
Ten-year median 1.0×
Current reading's percentile 100

P/S ratio against peers

Company P/S ratio
VTRS Viatris Inc. compare 1.5×
TAK Takeda Pharmaceutical Co. compare 2.2×
HLN Haleon PLC Sponsored ADR compare 2.3×
ELAN Elanco Animal Health Incorporated compare 2.4×
TEVA Teva Pharmaceutical Industries Ltd. 2.8×
ZTS Zoetis Inc. compare 3.6×
RDY Dr. Reddy's Laboratories Ltd compare 3.6×
NBIX Neurocrine Biosciences, Inc. compare 4.4×
UTHR United Therapeutics Corporation compare 7.6×
Drug Manufacturers Specialty & Generic industry median 2.1×
Healthcare sector median 3.5×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on TEVA